Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sofinicline
- Development stage
- Phase 2
- Lead developer
- AbbVie
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Sofinicline is a small molecule investigational drug that acts as an agonist of the nicotinic acetylcholine receptor, specifically targeting the α4β2 subtype. It was developed as a potential non-stimulant treatment for attention-deficit/hyperactivity disorder (ADHD), with additional clinical trials exploring its use in diabetic neuropathies and neuralgia. Sofinicline has demonstrated efficacy similar to atomoxetine in early-phase studies and appears to be well tolerated, though further evaluation is needed to determine optimal dosing and broader safety across populations. The drug has reached Phase II clinical trials but has not been approved for any indication[1][2][3][5].
- Other names
- SofiniclinSofinicline besylatesofiniclina
02
Targets
Alpha-6-beta-2-containing neuronal nicotinic acetylcholine receptorα4β2 nAChR (Nicotinic acetylcholine receptor alpha4 beta2 subtype)
Beyond the preview
Go deeper on sofinicline.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sofinicline.